Linear Clinical Research Ltd.

Nedlands, Western Australia 6009

3 studies enrolling now · 14 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors With KRAS G12C Mutations, Bile Duct Cancer, Bladder Cancer, Breast Cancer, Castration Resistant Prostatic Cancer, Cervical Cancer, Cholangiocarcinoma, Chronic Hepatitis B, Chronic Lymphocytic Leukemia, Clear Cell RCC

Studies at this site

• Study in Advanced Solid Tumor Patients — Recruiting now
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors — Recruiting now
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. — Running, not enrolling
• A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation — Stopped early
• Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) — Running, not enrolling
• Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma — Stopped early
• Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors — Stopped early
• An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. — Completed
• A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer — Completed
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors — Completed
• A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation — Stopped early
• A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B — Completed